

**PATENT COOPERATION TREATY**  
**PCT**  
**THIRD PARTY OBSERVATION**  
**(PCT Administrative Instructions Part 8)**

Applicant's or agent's file reference 0614-00099	
International application number PCT/IB2022/051486	International filing date (day/month/year) 19 Feb 2022 (19/02/2022)
Applicant UNIVERSITATSSPITAL BASEL	
Third party observation submitted by Sisi LI	Observation submitted on behalf of Porta Sophia
Date of submission(day/month/year) 20 Jan 2023 (20/01/2023)	Language of observation English

**Basis and contents of observation**

1. The observation is made on the basis of the claims in the international application as filed.
2. The observation comprises:  
References to documents: 10  
Uploaded copies of documents: 8
3. Further explanations:  
Uploaded copies of documents: 0

**Citation # 1 (Patent/utility model) (# uploaded documents: 0):**

Country code: US	Publication number: 20200147038	Document kind code: A1	
Patent Applicant/Patent Owner: RUSS; Suzanne, RAZ; Shlomi, FAMILY; Neiloufar		Title of invention:	
Link to document:			
Publication Date: 14 May 2020 (14/05/2020)	Filing Date:	Priority Date:	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: [0017], [0081], [0001], abstract, [0085], [0016]		Relevant to Claims: 1, 2, 8, 10	

Pending processing

Brief explanation of relevance:

From [0017]: "In some embodiments, the psychedelic agent is selected from ... 3,4,5-trimethoxyphenethylamine (mescaline)..." relevant to WO2022180497 claims 1, 2, 8, 10

From [0081]: "As used herein, a "psychedelic agent" refers to a compound capable of inducing an altered state of consciousness, i.e., a marked deviation in the subjective experience or psychological functioning of a normal individual from his or her usual waking consciousness. Altered states of consciousness can be monitored, evaluated, and/or quantified using any of a variety of methods known in the art including, without limitation, Dittrich's APZ (Abnormal Mental States) questionnaire, and its revised versions, OAV and 5D-ASC (see, for example, Dittrich et al., A Pharmacopsychiatry 1998, 31:80; Studerus et al., PLoS ONE 2010, 5)..." relevant to WO2022180497 claims 1

From Abstract: "The invention features methods of identifying a subject as being likely to have a positive therapeutic response to a psychedelic agent. Methods of the invention also include administering a psychedelic agent to a subject (e.g., a subject that has been identified as likely to respond positively thereto) to improve mental or physical well-being in the subject (e.g., by treating stress, anxiety, addiction, depression, compulsive behavior, by promoting weight loss, by improving mood, by treating or preventing a condition (e.g., psychological disorder), or by enhancing performance)." relevant to WO2022180497 claims 2

From [0001]: "Therapeutic benefits of psychedelic drugs, such as lysergic acid diethylamide and psilocybin, are being actively researched in humans. Studies in healthy volunteers have shown long-term increases in trait optimism (Carhart-Harris et al., Psychological Medicine 2016, 46:1379-1390), well-being (Id. and Griffiths et al., Psychopharmacology 2011, 218:649-665), and openness (Carhart-Harris et al., Psychological Medicine 2016, 46:1379-1390; MacLean et al., Journal of Psychopharmacology 2011, 25:1453-1461)" relevant to WO2022180497 claims 8

From [0085]: "As used herein, a "psychotherapy" refers to a non-pharmaceutical therapy in which the subject is psychologically engaged, directly or indirectly (e.g., by dialogue), in an effort to restore a normal psychological condition; to reduce the risk of developing a psychological condition, disorder, or one or more symptoms thereof; and/or to alleviate a psychological condition, disorder, or one or more symptoms thereof. Psychotherapy includes Behavioral Activation (BA), Cognitive Behavioral Therapy (CBT), Interpersonal psychotherapy (IPT), Psychoanalysis, Hypnotherapy, Psychedelic Psychotherapy, Psycholytic Psychotherapy, and other therapies. In some embodiments, a subject undergoes psychotherapy in conjunction with (e.g., prior to, during, and/or after) a pharmaceutical therapy, such as a psychedelic therapy." relevant to WO2022180497 claims 8

From [0052]: "In some embodiments, the methods of the invention can be used to treat a symptom of the psychological disorder (e.g., a psychosomatic symptom or a somatic symptom (e.g., chronic pain, anxiety disproportionate to severity of physical complaints, pain disorder, body dysmorphia, conversion, hysteria, neurological conditions without identifiable cause, or psychosomatic illness))" relevant to WO2022180497 claims 10

**Citation # 2(Web page) (# uploaded documents:1):**

Author:		Title of Page Or Article: Leminger's Scalines	
URL: <a href="https://web.archive.org/web/20201020135327/https://isomerdesign.com/countyourculture/2012/05/04/leminger-allylescaline/">https://web.archive.org/web/20201020135327/https://isomerdesign.com/countyourculture/2012/05/04/leminger-allylescaline/</a>			
DOI:			
Name of Website:		Publication Date: 20 Oct 2020 (20/10/2020)	Retrieval Date: 20 Jan 2023 (20/01/2023)
Most relevant passages or drawings: Figure of mescaline and novel phenethylamines , figure description, quote from Alexander Shulgin		Relevant to Claims:	
Brief explanation of relevance: From webpage figure of mescaline and novel phenethylamines relevant to WO2022180497 claims 1 From webpage: "(1) allylescaline, 3,5-dimethoxy-4-allyloxy-phenethylamine (2) proscaline, 3,5-dimethoxy-4-n-propoxy-phenethylamine (3) escaline, 3,5-dimethoxy-4-ethoxy-phenethylamine (4) MAPEA, 3-methoxy-4-allyloxy-phenethylamine (5) MEPEA, 3-methoxy-4-ethoxy-phenethylamine...I got a call out of absolutely nowhere, from a Stanislov Wistupkin, that he had discovered a number of new psychedelic drugs which he would like to share with me. They were simple phenethylamines , one with an ethoxy group at the 4-position, and one with an allyloxy group there. Both, he said, were mood elevators active between 100 and 300 milligrams... - Alexander Shulgin" relevant to WO2022180497 claims 1			

**Citation # 3(Periodical article) (# uploaded documents:1):**

Author: U Braun, G Braun, P Jacob 3rd, D E Nichols, A T Shulgin	Title of article: Mescaline analogs: substitutions at the 4-position	Title of Periodical: NIDA Research Monograph	Publication Date: 1978
Issue Number of Periodical: Volume 22	Publisher of Periodical:	Place of publication:	
Page range of article within periodical:	ISBN:	ISSN:	
DOI:			
Most relevant passages or drawings: Table 1, page 34		Relevant to Claims: 1, 4, 5, 6	
Brief explanation of relevance: Table 1 relevant to WO2022180497 claims 1, 4, 5, 6 From page 34: "These three mescaline analogs (table I) have been assayed in normal subjects by procedures previously outlined (Shulgin et al. 1969). Both of the alkoxy homologs are effective as psychotomimetics at dosages of 60 mg orally, with clear threshold effects being noted in some subjects at levels as low as 10 mg. These bases differ from mescaline in that the onset of action occurs sooner (within the first hour) and there is no nausea noted, but otherwise the time course and much of the qualitative content of the intoxication are similar to those of mescaline." relevant to WO2022180497 claims 1, 4, 5, 6			

Citation # 4 (Patent/utility model) (# uploaded documents: 0):

Country code: US	Publication number: 20210015833	Document kind code: A1	
Patent Applicant/Patent Owner: LaRosa; Tony, Davidson; Robert, Reid; David		Title of invention: ORAL SOFT GEL CAPSULE CONTAINING PSYCHEDELIC COMPOUND	
Link to document:			
Publication Date: 21 Jan 2021 (21/01/2021)	Filing Date:	Priority Date:	
Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:
Most relevant passages or drawings: [0002], [0005]		Relevant to Claims: 2	
<p>Brief explanation of relevance:</p> <p>From [0002]: "The present invention provides for an oral soft gel capsule that includes: (i) a soft capsule shell; (ii) psychedelic compound selected from the group consisting of psilocybin, psilocin, mescaline,..." relevant to WO2022180497 claims 2</p> <p>From [0005]: "The present invention also provides for a method of treating in a subject at least one of obsessive compulsive disorder (OCD), depression, pain, irritability, fibromyalgia, post-traumatic stress disorder (PTSD), cluster headaches, paranoia, psychosis, anxiety, panic attacks, flashbacks, smoking addiction, alcohol addiction, drug addiction, and cocaine addiction..." relevant to WO2022180497 claims 2</p>			

Pending processing

Citation # 5(Periodical article) (# uploaded documents:1):

Author: A B WOLBACH Jr, E J MINER, H ISBELL	Title of article: Comparison of psilocin with psilocybin, mescaline and LSD-25	Title of Periodical: Psychopharmacologi a	Publication Date: 1962
Issue Number of Periodical: Volume 3	Publisher of Periodical:	Place of publication:	
Page range of article within periodical:	ISBN:	ISSN:	
DOI: 10.1007/BF00412109			
Most relevant passages or drawings: Page 219, page 220, page 221-222		Relevant to Claims: 3, 5, 7	
<p>Brief explanation of relevance:</p> <p>From page 219: "Experiments. Two experiments were performed. In the first experiment 10 subjects received in randomized order 0.75 mcg/kg and 1.5 meg/kg of LSD; 2.5 mg/kg and 5.0 mg/kg of mescaline; and 37.5 mcg/kg, 75 meg/kg and 150 mcg/kg of psilocybin. The data on LSD and mescaline are also being reported separately in a paper dealing with cross tolerance between mescaline and LSD (WoL~Acl~ et al., in press). In the second experiment, 5 different subjects received in randomized order 37.5 and 75.0 mcg/kg of psilocin and 75 and 150 mcg/kg of psilocybin ." relevant to WO2022180497 claims 3, 5</p> <p>From page 220: "Drugs. All drugs were given intramuscularly at 8 a.m. Mescaline Hydrochloride" relevant to WO2022180497 claims 3, 5</p> <p>From page 221-222: "Psilocin appeared to differ from LSD and mescaline only in potency and time course. Symptoms after psilocin appeared within a few minutes, were nearly at peak within 30 minutes, and had largely sub-sided in less than 4 hours. Peak effects of LSD occurred in 1-1/2 hours, and were largely dissipated within 5 to 6 hours. The peak effects after mescaline occurred at 2 to 2 1/2 hours and persisted longer than the effects of either LSD or psilocin." relevant to WO2022180497 claims 3, 5</p> <p>From page 221 "Table. Total course of the psilocin reaction" relevant to WO2022180497 claims 7</p> <p>From page 221 "For comparison, values obtained after administration of a placebo taken from another experiment (Isbell 1959) are included in this table. Data on LSD and mescaline can be found in the paper of Wolbach et al. (1962), Like LSD and mescaline, psilocin caused significant increases in body temperature, systolic blood pressure, pupillary diameter and decreased the threshold for kneejerk." relevant to WO2022180497 claims 7</p>			

Pending Prosecution

Citation # 6(Web page) (# uploaded documents:1):

Author:		Title of Page Or Article: A Lysergic-Mescalito Experience LSD & Mescaline	
URL: <a href="https://erowid.org/experiences/exp.php?ID=100568">https://erowid.org/experiences/exp.php?ID=100568</a>			
DOI:			
Name of Website:	Publication Date: 13 Oct 2019 (13/10/2019)	Retrieval Date: 20 Jan 2023 (20/01/2023)	
Most relevant passages or drawings: Table, quotes from post		Relevant to Claims:	
<p>Brief explanation of relevance:</p> <p>From webpage: "So, I had decided having experienced synthetic mescaline twice before at decent dosages, I would experiment by combining it with LSD, as this was the last of my stash and I had heard great things about this particular combination and here was an opportunity to try it. I'd really enjoyed the past mescaline experiences but found the visual domain much less inspiring than what I experience with cactus, so I hoped that the LSD would more fully open the doors of our visual perception. My sister and I were taking 650mg (approx) of the mescaline, and one and half tabs of acid. My friend is sensitive to the nausea of mescaline so he took around 500mg with two tabs of the acid... The come up was gentle, the acid first. I felt some stomach awareness but this passed, and I didn't purge this time with the mescaline, or feel much in the way of nausea. The last two times I did. My friend was sick and felt better immediately." relevant to WO2022180497 claims 6</p>			

Pending processing

Citation # 7(Periodical article) (# uploaded documents:1):

Author: Vincent De Paul Lynch, Emmett Clemente, Steven Carson	Title of article: Effect of mescaline on cardiopulmonary dynamics. Method for determination of right ventricular pressure in the guinea pig	Title of Periodical: Journal of Pharmaceutical Sciences	Publication Date: 1967
Issue Number of Periodical: Volume 56/Issue 4	Publisher of Periodical:	Place of publication:	
Page range of article within periodical:	ISBN:	ISSN:	
DOI: 10.1002/jps.2600560411			
Most relevant passages or drawings: Abstract, page 477, page 483		Relevant to Claims: 7	
<p>Brief explanation of relevance:</p> <p>From abstract: "The effect of mescaline on respiratory dynamics, right ventricular pressure, and the ECG in the guinea pig is presented. A procedure for the acquisition of normal right ventricular pressure is described. The mean value for the latter was <math>13.4 \pm 4.6</math> mm. Hg. Mescaline in low dosages (1 to 20 mg./Kg.) produced a slight increase in heart rate; higher dosages (50 to 240 mg./Kg.) induced bradycardia and conduction disturbances. Respiratory rate, resistance of the airways, and minute volume increased significantly, while tidal volume and compliance decreased. The decrease in compliance was near maximum (-70 and - 77 per cent) with high dosages (50 and 100 mg./Kg.). Right ventricular pressure increased, average 45 per cent, following moderate dosages of mescaline (25 mg./Kg.)" relevant to WO2022180497 claims 7</p> <p>From 477: "In view of this concept, studies were conducted to observe the effect of mescaline on the cardiopulmonary system in the guinea pig. The investigation was divided into three phases: the effect of mescaline on (a) the electrocardiogram, (b) right ventricular pressure, and (c) respiratory dynamics" relevant to WO2022180497 claims 7</p> <p>From 483: "Low doses of mescaline produced a slight increase in heart rate; however, higher doses produced bradycardia. The latter effect was also reported by Speck (9). Because the rise in blood pressure parallels the fall in heart rate, a baroreceptor mechanism appears to be, at least partly, responsible for the bradycardia. The effect of mescaline on the ECG was not remarkable at low dosages (1,3, 8, 10, and 20 mg./Kg.)" relevant to WO2022180497 claims 7</p>			

Pending prior art

## Citation # 8(Periodical article) (# uploaded documents:1):

Author: A B WOLBACH Jr, H ISBELL, E J MINER	Title of article: Cross tolerance between mescaline and LSD-25 with a comparison of the mescaline and LSD reactions	Title of Periodical: Psychopharmacologi a	Publication Date: 1962
Issue Number of Periodical: Volume 12	Publisher of Periodical:	Place of publication:	
Page range of article within periodical:	ISBN:	ISSN:	
DOI: 10.1007/BF00413101			
Most relevant passages or drawings: Table 2, page 6, page 5, page 8, table 5, page 2		Relevant to Claims: 7, 12	
Brief explanation of relevance: From page 6: "table 2." relevant to WO2022180497 claims 7 From page 5: "The difference in the various area measurements after 1.5 meg/kg of LSD on the first and second controls were evaluated by a t-test for paired observations (EDWARDS). Data on the two sets of controls after 5.0 mg/kg of mescaline were treated similarly. Increase in blood pressure was significantly greater after LSD. There were no significant differences on other parameters ( Table 2)." relevant to WO2022180497 claims 7 From page 8: "table 5." relevant to WO2022180497 claims 7, 14 From page 8: "Both drugs induced anxiety, alterations in mood (generally "euphoric"), difficulty in thinking and concentration, sensory perceptual distortion particularly visual, and both caused true- and pseudo-hallucinations. The subjective symptoms reported after mescaline were very similar to those described in the literature. Table 5 illustrates the similarity of the patterns of the subjective response after LSD and mescaline" relevant to WO2022180497 claims 7, 14 From page 2: "Drugs and doses. LSD tartrate and mescaline hydrochloride were administered intramuscularly in doses of 0.75 mcg/kg and 1.5 mcg/kg (LSD)), and 2.5 mg/kg and 5.0 mg/kg ( mescaline). The drug concentrations employed for LSD and mescaline were 30 mcg/ml and 1000mg/ml respectively, in distilled water." relevant to WO2022180497 claims 7			



Citation # 9(Web page) (# uploaded documents:1):

Author:		Title of Page Or Article: The Grinch Who Took Mescaline	
URL: <a href="https://erowid.org/experiences/exp.php?ID=11253">https://erowid.org/experiences/exp.php?ID=11253</a>			
DOI:			
Name of Website:	Publication Date: 13 Dec 2001 (13/12/2001)	Retrieval Date: 20 Jan 2023 (20/01/2023)	
Most relevant passages or drawings: Table, quotes from post		Relevant to Claims:	
<p>Brief explanation of relevance:</p> <p>From table relevant to WO2022180497 claims 8, 13</p> <p>From webpage: “When I was getting confused I kept thinking, 'this must be a dream I'll wake up from' -- I contemplated what it would be like to be in a catatonic state of 'not remembering who I am' yet I didn't let that send me into a panic. I just accepted it, reminding myself there's a beginning, a middle and an end -- these words seemed to hold a vague meaning (again, this phrase was something the sitter had suggested we tell ourselves if we felt 'stuck'), but I didn't try to figure it out, I just trusted instead. I also thought, 'I am right here right now, and that's just where I need to be.' I felt cuddly and snuggly, and as the afternoon wore on I thought I really wanted physical contact, hugging, how nice it would feel. I did snuggle a little with two of the other trippers as I returned to baseline. I wanted to be near people, to connect” relevant to WO2022180497 claims 8</p> <p>From webpage: “It was the third and last group session of a course of tripping that spanned nine months. The material was mescaline again, 300 mg, taken in three doses spaced 45 min. apart, starting at about 1 PM... The poetry that I discerned in this answer helped to smooth me out and get beyond my temporary obsession with my heart, which stemmed from a period of anxiety disorder and panic attacks when I was 19 (see the 'terror blossom' report)... So I finally kept a promise to myself, by starting yoga. I also decided to abstain from drinking any alcohol for six months, just to see what that's like, and to explore Cannabis, which I discovered I've been chronically overdosing myself on for years (for an illustration, read any of my old Cannabis trip reports)” relevant to WO2022180497 claims 13</p>			

Pending process

Citation # 10(Periodical article) (# uploaded documents:1):

Author: I STEVENSON	Title of article: Comments on the psychological effects of mescaline and allied drugs	Title of Periodical: The Journal of Nerves and Mental Disease	Publication Date: 1957
Issue Number of Periodical: Volume 125/Issue 3	Publisher of Periodical:	Place of publication:	
Page range of article within periodical:	ISBN:	ISSN:	
DOI: 10.1097/00005053-195707000-00017			
Most relevant passages or drawings: Page 439, page 440		Relevant to Claims: 9	
Brief explanation of relevance: From page 439: "Another relevant experience is the subject's realization of the instability of his own perceptions and of his own thought images. He may have acquired a strengthened awareness of his own self." relevant to WO2022180497 claims 9 From page 440: "Some-thing like this may also explain what happens during the mescaline experience. Watching the images pass before the observing self, the subject may suddenly have a realization of the separateness of that Self from the images." relevant to WO2022180497 claims 9			

Pending processing

**PATENT COOPERATION TREATY**  
**PCT**  
**THIRD PARTY OBSERVATION**  
**(PCT Administrative Instructions Part 8)**

Applicant's or agent's file reference 0614-00099	
International application number PCT/IB2022/051486	International filing date (day/month/year) 19 Feb 2022 (19/02/2022)
Applicant UNIVERSITATSSPITAL BASEL	
Third party observation submitted by Taylor KURTZWEIL	Observation submitted on behalf of Porta Sophia
Date of submission(day/month/year) 20 Jan 2023 (20/01/2023)	Language of observation English

**Basis and contents of observation**

1. The observation is made on the basis of the claims in the international application as filed.
2. The observation comprises:  
References to documents: 4  
Uploaded copies of documents: 1
3. Further explanations:  
Uploaded copies of documents: 0

**Citation # 1 (Patent/utility model) (# uploaded documents: 0):**

Country code: US	Publication number: 20190246591	Document kind code: A1
Patent Applicant/Patent Owner: INSECTERGY, LLC/ Leo; Daniel Michael		Title of invention: INSECT AND CANNABIS PRODUCTION SYSTEMS AND METHODS
Link to document:		
Publication Date: 15 Aug 2019 (15/08/2019)	Filing Date: 26 Apr 2019 (26/04/2019)	Priority Date: 31 May 2017 (31/05/2017)
Source of Abstract:	Accession number:	Publication Date of Abstract: Retrieval Date of Abstract:
Most relevant passages or drawings: [2093], [0598]		Relevant to Claims: 10
Brief explanation of relevance: From [2093]: "In embodiments, the concentrated volatiles may be mixed with serotonin, psilocybin, psilocin, baeocystin, lysergic acid diethylamide (LSD), or mescaline." relevant to WO2022180497 claim 10  From [0598]: "In embodiments, the psilocybin mushrooms and/or the alimentary composition. improves memory and cognition, motor skills and coordination, the ability to solve complex computer coding challenges, hearing, vision, sensory function, learning, or neurogenesis..." relevant to WO2022180497 claims 10		

Citation # 2(Web page) (# uploaded documents:0):

Author:		Title of Page Or Article: Mescaline Dosage by Erowid	
URL: <a href="https://erowid.org/chemicals/mescaline/mescaline_dose.shtml">https://erowid.org/chemicals/mescaline/mescaline_dose.shtml</a>			
DOI:			
Name of Website: Erowid	Publication Date: 21 Feb 2015 (21/02/2015)	Retrieval Date: 20 Jan 2023 (20/01/2023)	
Most relevant passages or drawings: Table		Relevant to Claims: 11	
Brief explanation of relevance: Doses from table: "Threshold 100 mg, Light 100 - 200 mg, Common 200 - 300 mg, Strong 300 - 500 mg, Heavy 500 - 700 mg" relevant to WO2022180497 claim 11			

Citation # 3(Web page) (# uploaded documents:0):

Author:		Title of Page Or Article: The Point of It All LSD & Mescaline	
URL: <a href="https://erowid.org/experiences/exp.php?ID=106923">https://erowid.org/experiences/exp.php?ID=106923</a>			
DOI:			
Name of Website: Erowid	Publication Date: 15 Jun 2020 (15/06/2020)	Retrieval Date: 20 Jan 2023 (20/01/2023)	
Most relevant passages or drawings: Table, quotes from post		Relevant to Claims: 12, 13, 15, 16	
Brief explanation of relevance: From table: "DOSE: T+ 0:00 750 mg oral Mescaline T+ 1:30 oral LSD T+ 23:30 repeated vaporized Cannabis (extract)", relevant to WO2022180497 claims 12,13, 15, 16  From webpage: "Just as the legend goes in fear and loathing, the mescaline HCl came on slow, then I started cursing the guy who sold it to me, and then...intensity...I lit some incense, turned on the TV, and somewhat hesitantly dosed the 1000 ug of LSD....Literally before I knew it, another half hour had passed, and I was there. The Dead Zone. My ego was no more, completely eradicated and shut in a dark closet like a parent giving their child a time out." relevant to WO2022180497 claims 12, 15, 16  From webpage: "I am an extremely introverted person, and suffer from moderate social anxiety... Since my trip, I have made many changes to my life. I go to bed and wake up and more reasonable times, think carefully about every dietary choice I make, I exercise regularly, have significantly less social anxiety, and overall feel much more optimistic about the future. I've already lost almost 10 pounds just making these changes for a little under a week because of how much exercise I have been doing. I feel great! I can't remember the last time I felt so youthful, and the best part is that I still have so far to go. I absolutely can't wait to see how I look and feel after 3 months!" relevant to WO2022180497 claims 13			

Citation # 4(Periodical article) (# uploaded documents:1):

Author: Grinspoon, Lester; Bakalar, James B.	Title of article: Can Drugs Be Used to Enhance the Psychotherapeutic Process?	Title of Periodical: American Journal of Psychotherapy	Publication Date: 1986
Issue Number of Periodical: Volume 40 Issue 3	Publisher of Periodical:	Place of publication:	
Page range of article within periodical:	ISBN:	ISSN:	
DOI: 10.1176/appi.psychotherapy.1986.40.3.393			
Most relevant passages or drawings: Pages 394-395		Relevant to Claims: 8	
Brief explanation of relevance: From page 394-395: "There was also interest in making therapeutic use of the powerful psychedelic experiences of regression, abreaction, intense transference, and symbolic drama to improve or speed up psychodynamic psychotherapy. Two basic kinds of therapy emerged, one aimed at exploring the psychodynamic unconscious and the other making use of a mystical or conversion experience. The first type, psycholytic (literally, mind-loosening) therapy, required relatively small doses and several or even many sessions with LSD, mescaline, or psilocybin" relevant to WO2022180497 claim 8			

Pending processing